Drugs / 1XP HEPTAVAX™-II
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01463683 Comparator | Nov 2011 → Nov 2012 | hepatitis B virus infection | Merck Sharp & Dohme LLC | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 1XP HEPTAVAX-II | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01463683 ↗ |
| Known as | Heptavax-II | “In this study (NCT01463683), the immunogenicity and safety of a modified-process hepatitis B vaccine (mpHBV) were compared to those of the licensed Heptavax®-II.” PMID 29553862 ↗ Apr 2018 |
| Route | Subcutaneous | “1XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6” NCT01463683 ↗ |